Natural/Endogenous Targets
Target Interleukin-17 receptor

Selectivity at catalytic receptors
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference Interleukin-17 receptor Hs Agonist Agonist - - - ⤷

Selectivity at ligand targets
Key to terms and symbols		Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference COVA322 Hs None Binding 10.4 pKd - 20 ⤷ pKd 10.4 (Kd 3.6x10-11 M) [20] Description: Binding affinity determined using BIAcore technology.

Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols	Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference sonelokimab Hs Antibody Binding 12.4 pKd - 5 ⤷ pKd 12.4 (Kd 4x10-13 M) [5] vunakizumab Hs Antibody Binding >12.0 pKd - 21 ⤷ pKd >12.0 (Kd <1x10-12 M) [21] Description: Measured using Biacore technology ixekizumab Hs Antibody Binding >11.7 pKd - 2 ⤷ pKd >11.7 (Kd <2x10-12 M) [2] Description: Binding affinity of mAbs 104, 121 and 126 from patent US7838638 tibulizumab Hs Antibody Binding 10.9 pKd - 3 ⤷ pKd 10.9 (Kd 1.4x10-11 M) [3] bimekizumab Hs Antibody Binding 10.7 pKd - 1 ⤷ pKd 10.7 (Kd 2.1x10-11 M) [1] Description: Biacore assay using recombinant human IL-17A secukinumab Hs Antibody Binding 9.9 pKd - 9 ⤷ pKd 9.9 (Kd 1.22x10-10 M) [9] Description: Binding affinity for recombinant human IL-17 xeligekimab Hs Antibody Binding 9.9 pKd - 19 ⤷ pKd 9.9 (Kd 1.39x10-10 M) [19] Description: Binding affinity determined by SPR gumokimab Hs Antibody Binding 9.3 pKd - 14 ⤷ pKd 9.3 (Kd 5.1x10-10 M) [14] Description: Binding affinity (of mAb 13E9 H3L2) to IL-17A (24-155) determined by biolayer interferometry (BLI) LY3509754 Hs Inhibitor Binding 8.7 pKd - 8 ⤷ pKd 8.7 (Kd 2.14x10-9 M) [8] Description: Binding affinity determined by surface plasmon resonance. compound 23 [PMID: 35767390] Hs Inhibitor Binding 7.5 pKd - 4 ⤷ pKd 7.5 (Kd 3.2x10-8 M) [4] Description: Binding affinity of 23 for hIL-17A in a SPR assay secukinumab Hs Antibody Binding 8.7 pIC50 - 9 ⤷ pIC50 8.7 (IC50 2.1x10-9 M) [9] Description: Inhibition of IL-17-induced IL-6 production by human dermal fibroblasts. compound 669 [WO2021055376A1] Hs Inhibitor Binding 5.0 – 7.0 pIC50 - 10 ⤷ pIC50 5.0 – 7.0 (IC50 1x10-5 – 1x10-7 M) [10] Description: Measuring inhibition of IL-17A/A activation of IL-17R signalling in a cell-based reporter assay remtolumab Hs Antibody Binding - - - ⤷